{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:22:24Z","timestamp":1793658144681,"version":"4.5.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009075","name":"Guangdong Academy of Sciences","doi-asserted-by":"publisher","award":["2024GDASZH-2024010102"],"award-info":[{"award-number":["2024GDASZH-2024010102"]}],"id":[{"id":"10.13039\/501100009075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009075","name":"Guangdong Academy of Sciences","doi-asserted-by":"publisher","award":["2024GDASZH-2024010101"],"award-info":[{"award-number":["2024GDASZH-2024010101"]}],"id":[{"id":"10.13039\/501100009075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009075","name":"Guangdong Academy of Sciences","doi-asserted-by":"publisher","award":["2022GDASZH-2022010110"],"award-info":[{"award-number":["2022GDASZH-2022010110"]}],"id":[{"id":"10.13039\/501100009075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118374","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:20:02Z","timestamp":1763630402000},"page":"118374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"P3","title":["Development of potent JAK1\/2 PROTAC degraders for the treatment of inflammatory bowel diseases"],"prefix":"10.1016","volume":"302","author":[{"given":"Gang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanghui","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinshan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuxun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4191-7643","authenticated-orcid":false,"given":"Hongliang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118374_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111805","article-title":"Discovery of small-molecule candidates against inflammatory bowel disease","volume":"185","author":"Bai","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118374_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114631","article-title":"Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of inflammatory bowel diseases","volume":"242","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118374_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116710","article-title":"Discovery of novel N2-indazole derivatives as phosphodiesterase 4 inhibitors for the treatment of inflammatory bowel disease","volume":"277","author":"Zheng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118374_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116914","article-title":"Identification of novel indolinone derivatives as CTSC inhibitors to treat inflammatory bowel disease by modulating inflammatory factors","volume":"280","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118374_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10620-021-06831-8","article-title":"Update: innate lymphoid cells in inflammatory bowel disease","volume":"67","author":"Luo","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejmech.2025.118374_bib6","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.2147\/JIR.S518155","article-title":"N4BP3 activates TLR4-NF-\u03baB pathway in inflammatory bowel disease by promoting K48-Linked I\u03baB\u03b1 ubiquitination","volume":"18","author":"Jiang","year":"2025","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.ejmech.2025.118374_bib7","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.3390\/jcm10235660","article-title":"Efficacy, safety and future perspectives of JAK inhibitors in the IBD treatment","volume":"10","author":"Dudek","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2025.118374_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7247238","article-title":"A comprehensive review and update on the pathogenesis of inflammatory bowel disease","volume":"2019","author":"Guan","year":"2019","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.ejmech.2025.118374_bib9","doi-asserted-by":"crossref","first-page":"7062","DOI":"10.3390\/ijms25137062","article-title":"Inflammatory bowel disease: a comprehensive analysis of molecular bases, predictive biomarkers, diagnostic methods, and therapeutic options","volume":"25","author":"Diez-Martin","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118374_bib10","first-page":"768","article-title":"Treatment strategies in inflammatory bowel diseases","volume":"120","author":"Stallmach","year":"2023","journal-title":"Dtsch Arztebl Int."},{"key":"10.1016\/j.ejmech.2025.118374_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118067","article-title":"An overview of small-molecule agents for the treatment of psoriasis","volume":"119","author":"Jin","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118374_bib12","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/13543776.2025.2477486","article-title":"Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 \u2013 2023)","volume":"35","author":"Shah","year":"2025","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2025.118374_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118374_bib14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2025.118374_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108517","article-title":"Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: a literature review","volume":"105","author":"Wang","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2025.118374_bib16","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/ibd\/izad300","article-title":"Single-center experience with upadacitinib for adolescents with refractory inflammatory bowel disease","volume":"30","author":"Spencer","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejmech.2025.118374_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","article-title":"JAK inhibitors for inflammatory bowel disease: recent advances","volume":"15","author":"Honap","year":"2024","journal-title":"Frontline Gastroenterol."},{"key":"10.1016\/j.ejmech.2025.118374_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1089099","article-title":"JAK inhibitors: a new dawn for oral therapies in inflammatory bowel diseases","volume":"10","author":"Herrera-deGuise","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.ejmech.2025.118374_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116167","article-title":"JAK1\/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis","volume":"171","author":"Wu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118374_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118374_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103395","article-title":"PROTAC technology: a new drug design for chemical biology with many challenges in drug discovery","volume":"28","author":"Guedeney","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118374_bib22","doi-asserted-by":"crossref","first-page":"12085","DOI":"10.1021\/acs.jmedchem.5c00950","article-title":"Discovery of a proteolysis-targeting chimera degrader of JAK2 as a potential therapeutic agent for JAK2-Mediated myeloproliferative neoplasms","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118374_bib23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1021\/acsmedchemlett.1c00650","article-title":"Development of potent and selective Janus kinase 2\/3 directing PG\u2013PROTACs","volume":"13","author":"Alcock","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118374_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129838","article-title":"Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities","volume":"109","author":"Zhang","year":"2024","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118374_bib25","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1021\/acs.jmedchem.5c00027","article-title":"Discovery of a highly potent and selective tyrosine kinase 2 (TYK2) degrader with in vivo therapeutic efficacy in a murine psoriasis model","volume":"68","author":"Xiong","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118374_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115326","article-title":"Hi-JAK-ing the ubiquitin system: the design and physicochemical optimisation of JAK PROTACs","volume":"28","author":"Shah","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118374_bib27","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/ajh.26712","article-title":"Jaktinib (JAK1\/2 inhibitor): a momelotinib derivative with similar activity and optimized dosing schedule","volume":"97","author":"Tefferi","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2025.118374_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108675","article-title":"Discovery of novel PDE4 degraders with in vivo anti-inflammatory efficacy","volume":"163","author":"Liu","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118374_bib30","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.bbi.2015.07.007","article-title":"Pituitary dendritic cells communicate immune pathogenic signals","volume":"50","author":"Glennon","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ejmech.2025.118374_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fgstr.2024.1335380","article-title":"The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis","volume":"3","author":"Paridaens","year":"2024","journal-title":"Front. Gastroenterol."},{"key":"10.1016\/j.ejmech.2025.118374_bib32","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1021\/acs.jcim.0c00589","article-title":"PRosettaC: Rosetta based modeling of PROTAC mediated ternary complexes","volume":"60","author":"Zaidman","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118374_bib34","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1021\/acs.jmedchem.4c02969","article-title":"Design, synthesis, and evaluation of selective PDE4 inhibitors for the therapy of pulmonary injury","volume":"68","author":"Li","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118374_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116930","article-title":"Development of selective heterocyclic PDE4 inhibitors for treatment of psoriasis","volume":"280","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118374_bib36","doi-asserted-by":"crossref","first-page":"20353","DOI":"10.1021\/acs.jmedchem.4c01804","article-title":"Design, synthesis, and biological evaluation of new selective PDE4 inhibitors for topical treatment of psoriasis","volume":"67","author":"He","year":"2024","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:02:53Z","timestamp":1773817373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425011390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":34,"alternative-id":["S0223523425011390"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118374","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of potent JAK1\/2 PROTAC degraders for the treatment of inflammatory bowel diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118374"}}